Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1973 Mar;27(3):203-11.
doi: 10.1038/bjc.1973.25.

Immunological studies in acute myeloid leukaemia: PHA responsiveness and serum inhibitory factors

Free PMC article

Immunological studies in acute myeloid leukaemia: PHA responsiveness and serum inhibitory factors

J S Walker et al. Br J Cancer. 1973 Mar.
Free PMC article

Abstract

Sera from 16 of 20 patients with AML at some stage of the disease inhibited the in vitro PHA transformation of normal lymphocytes assessed by measuring the rate of DNA synthesis after 67-70 hours; 42% of pretreatment sera were inhibitory. Inhibitory activity was overcome at PHA concentrations 2-3 times greater than the concentration which allowed maximum discrimination between NHS and leukaemia sera.PHA transformation of washed lymphocytes obtained from AML patients before treatment and when receiving induction or consolidation (cytoreductive) chemotherapy was reduced only when cultures contained a high proportion of primitive cells. Even in primitive cell contaminated cultures significant responses to PHA could be measured if conditions were modified to prevent increasing acidity.Reports of reduced in vitro immunological reactions in pretreatment and poor prognosis patients may therefore be due to the presence of primitive cells in culture, and in treated patients to the failure of chemotherapy to reduce the circulating primitive cell count. Serum inhibitory factors may have a significant immunosuppressive effect in vivo, but the accurate assessment of the role of immune mechanisms in AML should attempt the measurement of specific immunity.

PubMed Disclaimer

References

    1. Br Med J. 1971 Nov 6;4(5783):329-30 - PubMed
    1. Br Med J. 1972 Aug 19;3(5824):469 - PubMed
    1. Nature. 1973 Jan 12;241(5385):95-100 - PubMed
    1. Lancet. 1966 Jun 4;1(7449):1265-6 - PubMed
    1. Cancer. 1966 Dec;19(12):2019-23 - PubMed